Radiat Oncol J.  2012 Dec;30(4):197-204.

Molecular biomarkers in extrahepatic bile duct cancer patients undergoing chemoradiotherapy for gross residual disease after surgery

Affiliations
  • 1Department of Radiation Oncology, Seoul National University College of Medicine, Seoul, Korea. kyubokim@snu.ac.kr
  • 2Department of Radiation Oncology, Soonchunhyang University Hospital, Seoul, Korea.
  • 3Department of Pathology, Seoul National University College of Medicine, Seoul, Korea.

Abstract

PURPOSE
To analyze the outcomes of chemoradiotherapy for extrahepatic bile duct (EHBD) cancer patients who underwent R2 resection or bypass surgery and to identify prognostic factors affecting clinical outcomes, especially in terms of molecular biomarkers.
MATERIALS AND METHODS
Medical records of 21 patients with EHBD cancer who underwent R2 resection or bypass surgery followed by chemoradiotherapy from May 2001 to June 2010 were retrospectively reviewed. All surgical specimens were re-evaluated by immunohistochemical staining using phosphorylated protein kinase B (pAKT), CD24, matrix metalloproteinase 9 (MMP9), survivin, and beta-catenin antibodies. The relationship between clinical outcomes and immunohistochemical results was investigated.
RESULTS
At a median follow-up of 20 months, the actuarial 2-year locoregional progression-free, distant metastasis-free and overall survival were 37%, 56%, and 54%, respectively. On univariate analysis using clinicopathologic factors, there was no significant prognostic factor. In the immunohistochemical staining, cytoplasmic staining, and nuclear staining of pAKT was positive in 10 and 6 patients, respectively. There were positive CD24 in 7 patients, MMP9 in 16 patients, survivin in 8 patients, and beta-catenin in 3 patients. On univariate analysis, there was no significant value of immunohistochemical results for clinical outcomes.
CONCLUSION
There was no significant association between clinical outcomes of patients with EHBD cancer who received chemoradiotherapy after R2 resection or bypass surgery and pAKT, CD24, MMP9, survivin, and beta-catenin. Future research is needed on a larger data set or with other molecular biomarkers.

Keyword

Extrahepatic bile duct cancer; Chemoradiotherapy; Immunohistochemistry; Molecular biomarker

MeSH Terms

Antibodies
beta Catenin
Bile Ducts, Extrahepatic
Biomarkers
Chemoradiotherapy
Cytoplasm
Follow-Up Studies
Humans
Immunohistochemistry
Matrix Metalloproteinase 9
Medical Records
Proto-Oncogene Proteins c-akt
Retrospective Studies
Antibodies
Matrix Metalloproteinase 9
Proto-Oncogene Proteins c-akt
beta Catenin
Full Text Links
  • ROJ
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
    DB Error: unknown error